Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12592351 | 0.83 | CSNK2A1 (0.38) | PDK2CSNK2A1ADORA3HTTPARP1 | |
| Hydrochloric Acid SCHEMBL31329224 | 0.81 | CSNK2A1 (0.37) | PDK2CSNK2A1ADORA3HTTPARP1 | |
| SCHEMBL6358280 | 0.79 | CSNK2A1 (0.36) | CSNK2A1ADORA3HTTPARP1KDM4E | |
| SCHEMBL12496434 | 0.74 | ADORA3 (0.38) | CSNK2A1ADORA3 | |
| Hydrochloric Acid SCHEMBL22418855 | 0.74 | ADORA3 (0.38) | CSNK2A1ADORA3 | |
| SCHEMBL20564 | 0.74 | ADORA3 (0.38) | CSNK2A1ADORA3PARP1KDM4EKMT2A | |
| SCHEMBL9544738 | 0.71 | ADORA3 (0.40) | CSNK2A1ADORA3HTTPARP1KDM4E | |
| SCHEMBL2508107 | 0.70 | MGAM (0.56) | PARP1KDM4E | |
| SCHEMBL6474573 | 0.70 | CSNK2A1 (0.38) | CSNK2A1ADORA3HTTPARP1 | |
| SCHEMBL11012250 | 0.69 | KDR (0.48) | KDM4EMEN1KMT2ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223851-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223851-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, CKMT1A; CKMT1B | PDK2 448/4885PDK4 555/4885CSNK2A1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.